Insilico Reaches Clinical Milestone for AI-Designed NLRP3 Inhibitor

Insilico Medicine has announced a significant milestone in the development of its experimental drug candidate ISM8969, marking the first time the therapy has been administered to humans. The achievement represents the first clinical milestone in the company’s co-development partnership with Hygtia Therapeutics and highlights the growing role of artificial intelligence in advancing drug discovery.

ISM8969 is an orally available small-molecule inhibitor targeting the NLRP3 inflammasome, a key driver of inflammation in the body. The drug is being developed as a potential treatment for chronic neuroinflammation and a range of central nervous system disorders, including Parkinson’s disease. What makes the candidate particularly notable is its ability to penetrate the blood-brain barrier, a challenge that has limited the effectiveness of many therapies aimed at neurological diseases.

The first-in-human study is a Phase I clinical trial being conducted in Australia. The randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISM8969. Researchers will assess both single ascending doses and multiple ascending doses of the drug.

The trial is expected to enroll 80 healthy volunteers and 20 obese adults who are at risk of cardiovascular disease. In addition to standard safety and efficacy measurements, investigators will collect cerebrospinal fluid samples to determine how effectively the drug reaches the central nervous system. These data are expected to help guide future dose selection and provide important insights into the drug’s therapeutic potential.

Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, described the advancement as a major achievement for both the company and its collaboration with Hygtia Therapeutics. He noted that developing NLRP3 inhibitors capable of safely crossing the blood-brain barrier has long been a challenge across the pharmaceutical industry.

According to Ren, the company used its AI-powered drug discovery platform, Chemistry42, to optimize the molecule and achieve favorable permeability and strong preclinical performance. The transition from an AI-generated concept to human clinical testing demonstrates the increasing maturity of artificial intelligence in pharmaceutical research.

The NLRP3 inflammasome plays an important role in the body’s immune defense system. However, excessive activation of this pathway can lead to chronic inflammation and tissue damage, contributing to neurodegenerative diseases such as Parkinson’s disease. By inhibiting NLRP3 activity, ISM8969 aims to reduce harmful inflammation while supporting neuronal health and function.

Preclinical studies of ISM8969 produced encouraging results. The candidate demonstrated strong activity in laboratory testing, favorable safety characteristics, and promising pharmacological profiles in animal models. It also showed efficacy in multiple models of acute and chronic inflammatory diseases. Unlike several other NLRP3 inhibitors currently in development, ISM8969 is capable of reaching the brain, potentially allowing it to directly address inflammation within the central nervous system.

The program was officially nominated as a preclinical candidate in December 2024. To accelerate its development, Insilico entered into an exclusive global co-development agreement with Hygtia Therapeutics. Under the partnership, both companies share equal ownership of the program’s global rights and interests, while Insilico is responsible for leading regulatory submissions and the Phase I clinical study. The company also remains eligible for up to $66 million in upfront and milestone payments as development progresses.

The announcement also highlights Insilico’s broader progress as an AI-driven biotechnology company. The company reports that its AI and automation platforms have significantly reduced the time required for early-stage drug discovery. While traditional programs can take several years to identify a preclinical candidate, Insilico says it typically reaches that stage within 12 to 18 months while synthesizing and testing far fewer compounds.

Since 2021, the company has nominated 31 preclinical candidates, with 13 receiving investigational new drug approval or clearance. As it continues to expand its AI capabilities, Insilico is also developing tools such as MMAI Gym, a platform designed to train and evaluate scientific AI models for real-world research applications. Through these efforts, the company aims to further accelerate innovation in drug discovery and move closer to what it describes as the future of AI-powered pharmaceutical development.